Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
LYNPARZA tablets are indicated: in combination with abiraterone and prednisone/ prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated and as monotherapy for the treatment of adult patients with mCRPC and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent1
All materials for healthcare professionals are intended to be viewed online.
For further information on patient monitoring requirements before and during LYNPARZA treatment, see below or consult the SmPC.
Our Expert on Demand programme offers an opportunity for healthcare professionals to attend interactive virtual presentations and Q&A sessions. The programme provides a virtual platform to share best practices and discuss topics related to LYNPARZA (olaparib) combination treatment for 1L mCRPC.
Please see a list of available topics below:
Module 1: Time to challenge treatment options in 1L mCRPC; LYNPARZA in PROpel
Learn about the evolving landscape of 1L mCRPC therapy and key outcomes from the PROpel clinical trial data for LYNPARZA combination treatment
Module 2: Management of adverse events and monitoring patients on LYNPARZA in combination with abiraterone + prednisone/prednisolone
Examine the safety and tolerability profile of LYNPARZA combination treatment, including management of common and rare but serious adverse events through standard procedures or dose adjustments
Module 3: Exploring Frontiers in Prostate Cancer: Real-World PROpel Case Studies
A focused overview of managing mCRPC patients on LYNPARZA combination therapy, including real-world cases, survival outcomes by HRRm status, and handling common adverse events.
mCRPC=metastatic castration-resistant prostate cancer; PI=prescribing information.
GB-75647 | DOP: April 2026
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
GB-74216| DOP : February 2026
